Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Baert

Showing results (31-40 of 99) with videos related to

Pageof 10
Sort By:
Inflammatory Bowel Diseases|January 9, 2007
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resectionAndre Van Gossum, Olivier Dewit, Edouard Louis, et al.
Gastroenterology|April 29, 2008
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trialGert Van Assche, Charlotte Magdelaine-Beuzelin, Geert D'Haens, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 26, 2025
Long-term safety of ustekinumab in Crohn's disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort dataLaurent Peyrin-Biroulet, Maciej Nazar, Anna Sheahan, et al.
Inflammatory Bowel Diseases|July 29, 2009
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case seriesMarc Ferrante, Geert D'Haens, Olivier Dewit, et al.
The American Journal of Gastroenterology|November 12, 2020
Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIXPauline Rivière, Geert D'Haens, Laurent Peyrin-Biroulet, et al.
Patient Preference and Adherence|July 18, 2018
Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover studySéverine Vermeire, François D'heygere, Antoine Nakad, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 23, 2016
Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assaysSumin Bian, Thomas Van Stappen, Filip Baert, et al.
Gastroenterology|October 13, 2009
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's diseaseFilip Baert, Liesbeth Moortgat, Gert Van Assche, et al.
Gastroenterology|August 31, 2019
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Filip Baert, Silvio Danese, et al.
European Journal of Gastroenterology & Hepatology|February 28, 2024
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studiesGeert D'Haens, Filip Baert, Silvio Danese, et al.
Pageof 10

Showing results (31-40 of 99) with videos related to

Sort By:
Pageof 10
Inflammatory Bowel Diseases|January 9, 2007
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resectionAndre Van Gossum, Olivier Dewit, Edouard Louis, et al.
Gastroenterology|April 29, 2008
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trialGert Van Assche, Charlotte Magdelaine-Beuzelin, Geert D'Haens, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 26, 2025
Long-term safety of ustekinumab in Crohn's disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort dataLaurent Peyrin-Biroulet, Maciej Nazar, Anna Sheahan, et al.
Inflammatory Bowel Diseases|July 29, 2009
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case seriesMarc Ferrante, Geert D'Haens, Olivier Dewit, et al.
The American Journal of Gastroenterology|November 12, 2020
Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIXPauline Rivière, Geert D'Haens, Laurent Peyrin-Biroulet, et al.
Patient Preference and Adherence|July 18, 2018
Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover studySéverine Vermeire, François D'heygere, Antoine Nakad, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 23, 2016
Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assaysSumin Bian, Thomas Van Stappen, Filip Baert, et al.
Gastroenterology|October 13, 2009
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's diseaseFilip Baert, Liesbeth Moortgat, Gert Van Assche, et al.
Gastroenterology|August 31, 2019
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Filip Baert, Silvio Danese, et al.
European Journal of Gastroenterology & Hepatology|February 28, 2024
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studiesGeert D'Haens, Filip Baert, Silvio Danese, et al.
Pageof 10